PTC Therapeutics Introduces Employee Equity Incentives to Enhance Workforce and Drive Innovation

PTC Therapeutics Bolsters Workforce with New Employee Equity Incentives

PTC Therapeutics, Inc. announces the approval of non-statutory stock options and restricted stock units (RSUs) aimed at attracting and retaining talent within its innovative therapeutic landscape. On December 19, 2025, the company reveals the granting of 3,825 stock options and 4,385 RSUs to five new employees. This decision aligns with the organization's commitment to fostering a motivated workforce that is crucial to advancing its mission of developing therapies for individuals with rare disorders. The awards were issued in compliance with Nasdaq Listing Rule 5635(c)(4), ensuring that the company's practices adhere to regulatory standards.

The granted stock options feature an exercise price set at $75.42 per share, reflecting PTC's closing price on the grant date of December 16, 2025. Each stock option has a 10-year term and a vesting schedule that promotes long-term commitment, with 25% of the options vesting on the first anniversary of each employee's hire date. The remaining shares will vest at a rate of 6.25% every three months thereafter. This structured approach not only incentivizes employees but also aligns their success with the company’s growth and achievements, fostering a collaborative environment focused on patient outcomes.

Similarly, the RSUs will also vest over four years, with 25% of the units vesting on each annual anniversary of the hire date. By implementing these compensation packages, PTC Therapeutics strengthens its foundation as a leader in the biopharmaceutical industry. The company's dedication to discovering and commercializing transformative treatments remains steadfast, emphasizing the importance of a skilled and committed workforce to navigate the complexities of rare disease therapeutics. As PTC continues to expand its pipeline of innovative medicines, these equity incentives play a crucial role in supporting its mission and enhancing overall employee engagement.

In addition to these employee incentives, PTC Therapeutics maintains its focus on addressing unmet medical needs within the rare disease community. The company leverages scientific expertise and a robust global infrastructure to deliver best-in-class therapies for patients. Interested parties can learn more about PTC's ongoing initiatives and developments by visiting their website or engaging with their social media channels.

For media inquiries, Jeanine Clemente is available for contact, while investors can reach out to Ellen Cavaleri for further information. PTC Therapeutics remains committed to its vision of improving patient outcomes through innovative solutions in the biopharmaceutical sector.